Intravenous nedaplatin and intra-arterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer

Nedaplatin (254S) is a platinum analogue with less renal toxicity and a hig her efficacy for cervical cancer than cisplatin (CDDP). Intra-arterial admi nistration (IA) of CDDP is more effective than intravenous administration ( IV) for patients with cervical cancer. We treated 23 patients using TV 254S and IA cisplatin combined with TAE. The patients had cervical cancer in st ages IB2-IV 254S was administered on day 1 and 70 mg/m(2) of CDDP was admin istered via both uterine arteries by the Seldinger method on day 3. Thereaf ter, TAE was done. Treatment was repeated every 3 weeks for 2-3 cycles. The patients were aged 29 -72 (median: 52) years, with 6 in stage 1B2, 6 in 2A , 2 in 2B, 4 in 3B, and 5 in 4A (SCC: 16, adeno.:3, adeno-sq.:4). The respo nse was defined by MRI. It was PR in 65% (15/23), and CR in 35% (8/23), and the overall response rate was 100%. Myelosuppression was manageable. Grade 3/4 renal toxicity was observed in 2 patients. This regimen appears to be effective for locally advanced cervical cancer, especially SCC, but its inf luence on survival remains to be determined.